释 义 n. 氯卡色林
例 句 Wall Street analysts considered lorcaserin the most likely of three diet drugs before the FDA to succeed because it seemed to present fewer safety issues. 华尔街分析家认为氯卡色林很有可能在美国食品药品监督管理局批准之前三种减肥药中最成功的一个，因为该药物安全问题最少。
作者： Peter Rossing
Obesity is an established risk factor for chronic kidney disease (CKD) and has been associated with both impaired kidney function and albuminuria, reflecting a broad spectrum of underlying pathology. Proposed mechanisms include hemodynamic effects, with increased glomerular pressure leading to hyperfiltration and albuminuria, with subsequent declines in kidney function, as well as possible adverse effects of adipokines on podocyte health. In contrast to the well-established relationship between obesity and CKD, whether intentional weight loss improves kidney disease outcomes has been debated. This possibility was recently evaluated in a secondary analysis of a large randomized placebo-controlled trial, CAMELLIATIMI 61 (Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients). The CAMELLIA trial evaluated the cardiovascular safety of lorcaserin, a selective agonist of the 5-hydroxytryptamine (serotonin) 2C receptor that suppresses appetite through hypothalamic effects, in comparison with placebo, both in addition to behavioral counseling. Participants were overweight or obese adults either with or at high risk for cardiovascular disease. A prespecified secondary analysis assessed the impact of weight loss with lorcaserin versus placebo on development of a combined endpoint of new or worsening micro-or macro-albuminuria, new or worsening CKD, doubling of serum creatinine, end-stage renal disease, kidney transplant, or renal death. At baseline, the median estimated glomerular filtration rate (eGFR) was 76 ml/min per 1.73 m2 (interquartile range: 63–89 ml/min per 1.73 m2 ), approximately 20% of participants had a baseline eGFR. During a median of 3.3 years of follow up, a significant 13% reduction occurred in the combined CKD endpoint in the lorcaserin arm (hazard ratio 0.87; 95% confidence interval 0.79– 0.96). This change was driven by a significant reduction in the number of participants with new or worsening albuminuria (2.7% vs. 3.1%; HR 0.86, 95% CI 0.76–0.97) and new or worsening CKD stage (2.4% vs. 2.9%; HR 0.81, 95% CI 0.72–0.93). Other endpoints, including end-stage renal disease and 30% or 40% decline in eGFR, were rare, reflecting the relatively low CKD risk in the study population. The treatment effect was larger in the small subgroup without hypertension, but treatment effect had no interaction with baseline CKD stage, diabetes status, albuminuria level, or any other clinical characteristic. Modest effects on hemoglobin A1c and blood pressure did not fully explain the findings.